Analytical methods for nucleic acid drugs, etc.

By bubbling the mobile phase with an inert gas and using a non-aqueous solvent for the basic ion pair reagent, the method maintains high sensitivity in liquid chromatography-mass spectrometry analysis of nucleic acid drugs, addressing the issue of mobile phase deterioration and ensuring stable peak intensity over time.

JP7583020B2Active Publication Date: 2024-11-13LSI MEDIENCE CORPORATION
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022503664
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-07-17
Filing Date
2021-02-24
Publication Date
2024-11-13
Estimated Expiration
2041-02-24

AI Technical Summary

Technical Problem

Existing methods for analyzing nucleic acid drugs using liquid chromatography-mass spectrometry face challenges in maintaining high sensitivity over long periods due to deterioration of the mobile phase, particularly the basic ion pair reagent.

Method used

The method involves bubbling the mobile phase with an inert gas to remove oxygen and using a mobile phase containing a basic ion pair reagent in a non-aqueous solvent to prevent deterioration, thereby maintaining sensitivity over time.

Benefits of technology

This approach allows for continuous analysis of nucleic acid drugs with high sensitivity by preventing mobile phase degradation, ensuring accurate and stable peak intensity over extended periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583020000009
    Figure 0007583020000009
  • Figure 0007583020000010
    Figure 0007583020000010
  • Figure 0007583020000011
    Figure 0007583020000011
Patent Text Reader

Abstract

The present invention addresses the problem of providing a means for enabling liquid chromatography-mass spectrometry on ionic substances such as nucleic acid drugs to be performed continuously for long periods of time while maintaining high sensitivity throughout the analysis. Provided is an analyte analysis method that includes a step in which a specimen that includes an ionic analyte undergoes liquid chromatography using a mobile phase containing a basic ion-pair reagent and is further subjected to mass analysis, wherein the analysis method is characterized in that an operation for preventing the mobile phase from deteriorating is performed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for analyzing ionic substances such as nucleic acid drugs by liquid chromatography-mass spectrometry, which prevents deterioration of the mobile phase of liquid chromatography. Note that "analysis" in this specification includes "measurement" that determines the amount of the analyte qualitatively, quantitatively, or semi-quantitatively. [Background technology]

[0002] In recent years, the importance of analyzing trace substances contained in biological samples is increasing. In particular, there is a demand for highly accurate analysis of ionic substances such as mononucleotides, mononucleotide metabolites, modifications, oligonucleotides consisting of multiple nucleotides, sugars, and sugar chains, as well as biomarker proteins that are induced, lost, or otherwise affected by diseases. There is also a demand for a method to accurately analyze nucleic acid drugs as an analysis of ionic substances contained in biological samples.

[0003] Nucleic acid drugs are composed of oligonucleotides in which (modified) nucleic acids are linked together to form ten or several dozen bases, and are medicines that act directly on the body and are manufactured by chemical synthesis. Nucleic acid drugs have effects such as directly suppressing the expression of specific proteins in the body, and are expected to provide new treatment methods for diseases that have been difficult to treat until now. In addition, several nucleic acid drugs have already been approved for manufacture and sale.

[0004] When measuring ionic substances, for example, an analytical method using liquid chromatography-mass spectrometry is known as an analytical method for oligonucleotides (Patent Document 1). However, in the production management of pharmaceuticals, etc., it is desirable to use a more accurate analytical method that can perform analysis without decreasing sensitivity even in continuous analysis over long periods of time. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Special Publication No. 2012-500394 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention aims to provide a means for continuously analyzing ionic substances such as nucleic acid pharmaceuticals (hereinafter sometimes simply referred to as nucleic acid pharmaceuticals, etc.) over a long period of time using liquid chromatography-mass spectrometry while maintaining high sensitivity. [Means for solving the problem]

[0007] The present inventors have conducted extensive research to solve the above problems, and have found that when ionic substances such as nucleic acid drugs are measured by liquid chromatography-mass spectrometry, sensitivity decreases, particularly in long-term continuous analysis. They have also found that such sensitivity decreases in continuous analysis are caused by deterioration of the basic ion-pair reagent in the mobile phase. They have also found that deterioration of the mobile phase can be prevented by preventing deterioration of the basic ion-pair reagent in the mobile phase, and have completed the present invention based on this finding.

[0008] That is, the present invention is as follows. [1] An analytical method comprising the steps of subjecting a sample containing an ionic analyte to liquid chromatography using a mobile phase containing a basic ion pair reagent, and then subjecting the sample to mass spectrometry, A method for analyzing a substance to be analyzed, comprising carrying out an operation to prevent deterioration of the mobile phase. [2] The method according to [1], wherein the step of preventing deterioration of the mobile phase includes bubbling the mobile phase with an inert gas. [3] The method according to [2], wherein the operation of preventing deterioration of the mobile phase further comprises managing and controlling bubbling of the mobile phase with an inert gas. [4] The method according to any one of [1] to [3], wherein the operation of preventing deterioration of the mobile phase includes using a mobile phase containing a basic ion pair reagent in a non-aqueous solvent. [5] The method according to any one of [1] to [4], wherein the basic ion pair reagent is an amine compound. [6] Basic ion pair reagents include tetraethylammonium hydroxide (TEA-OH), tetrabutylammonium hydroxide (TBAOH), N,N-dimethylbutylamine (DMBA), octylamine (OA), tripropylamine (TPA), N,N-dimethylhexylamine (DMHA), diisopropylamine (DIPA), N-methyldibutylamine (MDBA), propylamine (PA), triethylamine (TEA), hexylamine (HA), tributylamine (TBA), N,N-dimethylcyclohexylamine (DMCHA), N,N-diisopropylethylamine (DIEA), tetramethylethylenediamine (TMEDA), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), dipropyl ammonium acetate (DPAA), dibutyl ammonium acetate (DBAA), diamyl ammonium acetate (DAAA), and dihexyl ammonium acetate (DHAA). [7] The method according to any one of [1] to [6], wherein the ionic analyte is at least one selected from a purine compound, a purine compound analog, a pyrimidine compound, or a nucleoside containing a pyrimidine compound analog; a nucleotide, a cyclic nucleotide, a nucleotide diphosphate, a nucleotide triphosphate; a coenzyme containing a nucleoside selected from nicotinamide adenine dinucleotide phosphate (NAD, NADPH), flavin adenine dinucleotide (FAD, FADH), coenzyme A, tetrahydromethanopterin (H4MPT), S-adenosylmethionine (SAM), and 3'-phosphoadenosine-5'-phosphosulfate; metabolic intermediates thereof, and reduced hydrogen acceptors and modified products thereof; an oligonucleotide, a sugar, and a sugar chain. [8] The method according to [7], wherein the oligonucleotide is at least one type of nucleic acid drug selected from antisense, decoy, siRNA, miRNA, ribozyme, CpG oligo and aptamer. [9] The method according to [7], wherein the sugar and the sugar chain are at least one selected from monosaccharides, disaccharides, and oligosaccharides.

[10] The method according to any one of [2] to [9], wherein the inert gas is at least one selected from the group consisting of nitrogen gas, argon gas, neon gas, krypton gas, xenon gas and helium gas.

[11] A method for detecting a chromatographic concentration of a basic ion pair reagent comprising the steps of bubbling a mobile phase of liquid chromatography containing a basic ion pair reagent; How to prevent mobile phase degradation.

[12] A method for preparing a mobile phase in which a basic ion pair reagent is dissolved in a non-aqueous solvent, mixing the mobile phase with a mobile phase containing water, and using the mobile phase for liquid chromatography. How to prevent mobile phase degradation.

[13] A liquid chromatography apparatus for separating a sample containing an ionic analyte, the apparatus using a mobile phase containing a basic ion pair reagent. A mass spectrometer for analyzing a target substance; and Device for preventing deterioration of mobile phase, An analysis device comprising:

[14] The analytical apparatus according to

[13] , wherein the device for preventing deterioration of the mobile phase is a gas bubbling device for the mobile phase.

[15] The analytical apparatus described in

[14] , wherein the device for preventing deterioration of the mobile phase further includes means and software for managing and controlling bubbling of the mobile phase.

[16] The analytical instrument according to

[13] , wherein the device for preventing deterioration of the mobile phase is a device for mixing a mobile phase containing a basic ion pair reagent in a non-aqueous solvent with a mobile phase containing water. Effect of the Invention

[0009] According to the present invention, in liquid chromatography-mass spectrometry of ionic substances such as nucleic acid pharmaceuticals, continuous analysis over a long period of time is possible while maintaining high sensitivity. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 shows the transitions of peak area values ​​of mipomersen-MOE and mipomersen-S oligo (160 consecutive analyses) when nitrogen bubbling was not performed. [Diagram 2] FIG. 2 shows the transition of the peak area ratio of mipomersen-MOE / mipomersen-S oligo (160 consecutive analyses) when nitrogen bubbling was not performed. [Diagram 3] FIG. 3 shows the transition of peak area values ​​of mipomersen-MOE and mipomersen-S oligo when nitrogen bubbling was applied (160 consecutive analyses). [Figure 4] FIG. 4 shows the change in the peak area ratio of mipomersen-MOE / mipomersen-S oligo when nitrogen bubbling was applied (160 consecutive analyses). [Diagram 5] FIG. 5 shows the transition of the peak area value of mipomersen-MOE (240 consecutive analyses) when nitrogen bubbling was not performed. [Figure 6] FIG. 6 shows the transition of the peak area value of mipomersen-OMe (240 consecutive analyses) when nitrogen bubbling was not performed. [Figure 7] FIG. 7 shows the transition of the peak area value of mipomersen-LNA (240 consecutive analyses) when nitrogen bubbling was not performed. [Figure 8] FIG. 8 shows the transition of the peak area value of mipomersen-MOE when nitrogen bubbling was applied (240 consecutive analyses). [Figure 9] FIG. 9 is a graph showing the transition of the peak area value of mipomersen-OMe when nitrogen bubbling was applied (240 consecutive analyses). [Figure 10] FIG. 10 shows the transition of the peak area value of mipomersen-LNA when nitrogen bubbling was applied (240 consecutive analyses). [Figure 11] FIG. 11 shows the results of identifying the mobile phase causing the deterioration. [Figure 12] FIG. 12 is a diagram showing the transition of the peak area value of CS-A with and without nitrogen bubbling (52 consecutive analyses). [Figure 13] FIG. 13 is a diagram showing the transition of peak area values ​​of CS-E with and without nitrogen bubbling (52 consecutive analyses). [Figure 14] FIG. 14 shows the transition of peak area value of an internal standard substance (ΔUA-2S GlcNCOEt-6S) with and without nitrogen bubbling (240 consecutive analyses). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] Hereinafter, an embodiment of the present invention will be described. <Analysis method for target substances> One aspect of the present invention relates to a method for analyzing an analyte, comprising the steps of subjecting a sample containing an ionic analyte to liquid chromatography using a mobile phase containing a basic ion pair reagent, and then subjecting the sample to mass spectrometry, characterized in that an operation is performed to prevent deterioration of the mobile phase (hereinafter, sometimes referred to as the "analytical method of the present invention").

[0012] The basic ion pair reagent used in the present invention is not particularly limited as long as it is a basic compound capable of forming an ion pair with an ionic analyte in the mobile phase, but a basic compound such as an amine compound is preferably used. Examples of the amine compound include aliphatic amines having an alkyl group having 1 to 10 carbon atoms (preferably 2 to 8 carbon atoms, 2 to 6 carbon atoms, etc.), aromatic amines having 6 to 20 carbon atoms, heterocyclic amines having 3 to 20 carbon atoms, and salts thereof. Examples of the salt include, but are not limited to, bromides, chlorides, hydroxides, sulfates, nitrates, hydrochlorides, acetates, etc. Examples of basic compounds that are amine compounds include tetraethylammonium hydroxide (TEA-OH), tetrabutylammonium hydroxide (TBAOH), N,N-dimethylbutylamine (DMBA), octylamine (OA), tripropylamine (TPA), N,N-dimethylhexylamine (DMHA), diisopropylamine (DIPA), N-methyldibutylamine (MDBA), propylamine (PA), triethylamine (TEA), hexylamine (HA), tributylamine (TBA), N,N-dimethylcyclohexylamine (DMCHA), N,N-diisopropylethylamine (DIEA), tetramethylethylenediamine (TMEDA), 1,8-diazabicyclo[5.4.0]undec-7-ene Examples of basic ion pair reagents include, but are not limited to, dipropylammonium acetate (DPAA), dibutylammonium acetate (DBAA), diamylammonium acetate (DAAA), and dihexylammonium acetate (DHAA). Those skilled in the art can select an appropriate basic ion pair reagent for each analyte and use it under appropriate conditions. One or more basic ion pair reagents may be used.

[0013] The present inventors have conducted extensive research into a means for continuously analyzing ionic analytes such as nucleic acid drugs while maintaining high sensitivity in liquid chromatography-mass spectrometry. The present inventors have found a phenomenon in which peak intensity decreases over time in liquid chromatography-mass spectrometry of ionic analytes such as nucleic acid drugs. The present inventors have hypothesized that in order to prevent the sensitivity from decreasing over time in continuous analyses, it is necessary to prevent the degradation of basic ion pair reagents, and have investigated a means for preventing the degradation. As a result, it was discovered that, as a first measure, by bubbling the mobile phase of liquid chromatography with an inert gas to remove oxygen from the mobile phase, it is possible to prevent deterioration of the basic ion pair reagent and suppress a decrease in sensitivity in liquid chromatography-mass spectrometry. Furthermore, as a second method, the researchers discovered that by preparing a mobile phase containing a basic ion pair reagent in a non-aqueous solvent and mixing it with a mobile phase containing water just before injection into liquid chromatography, it is possible to prevent deterioration of the basic ion pair reagent and suppress a decrease in sensitivity in liquid chromatography-mass spectrometry. The present invention has thus been made.

[0014] ≪Deterioration prevention process≫ A more specific embodiment of the present invention relates to the analytical method of the present invention, wherein the operation of preventing deterioration of the mobile phase includes bubbling the mobile phase with an inert gas. The bubbling can be carried out by any mode capable of removing oxygen from the mobile phase, for example, by using a gas bubbling device that blows an inert gas into a container that holds the mobile phase to perform bubbling. The flow rate of the inert gas can be changed depending on the measurement environment, sample, mobile phase used, total amount of mobile phase, etc., and is not particularly limited, but examples thereof include amounts of 0.1 to 200 mL / min, preferably 0.1 to 20 mL / min, and more preferably 0.1 to 10 mL / min, per 1 L of mobile phase. The inert gas may be blown continuously or intermittently, and the amount of the inert gas blown may be reduced all at once or in stages. The flow rate of the inert gas may be measured, for example, using an Agilent ADM1000. As a specific bubbling method, a person skilled in the art can appropriately set the flow rate in consideration of the size, shape, and airtightness of the container in which the mobile phase is contained, within a range that does not affect the composition of the mobile phase or the separation of liquid chromatography. For example, the flow rate of the inert gas supplied may be changed to 0.1 to 10 mL / min after degassing using an ultrasonic bath immediately after preparation of the mobile phase and bubbling with an inert gas at about 100 mL / min for several minutes.

[0015] One non-limiting embodiment of a gas bubbling device for use in bubbling a mobile phase is described below. The gas bubbling device is provided with an inert gas supply pipe for blowing in the supplied high purity inert gas. The inert gas supply pipe is inserted into the mobile phase container. The material, shape, and installation position (depth in the mobile phase, etc.) of the inert gas supply pipe may be appropriately selected based on the usual method. The gas bubbling device may also be provided with a flow rate control valve for adjusting the flow rate of the inert gas flowing through the inert gas supply pipe. The gas bubbling device blows the inert gas at a flow rate adjusted by the flow rate control valve into the mobile phase in the mobile phase container through the inert gas supply pipe to perform the bubbling process. In addition, an exhaust pipe may be provided to exhaust the oxygen-containing air exhausted from the mobile phase to the outside of the container. In addition, the gas bubbling device may further include a device for managing and controlling the gas bubbling by the gas bubbling device, a control computer, or other means, and the performance of the management and control device may be to control whether to perform or stop bubbling at regular intervals. The system may further include a management and control device that manages and controls the gas bubbling device based on the dissolved oxygen concentration measured by the concentration meter, and the management and control device may increase the amount of inert gas injected by the gas bubbling device when the dissolved oxygen concentration measured by the concentration meter becomes equal to or greater than a predetermined value, thereby controlling the gas bubbling device so that the dissolved oxygen concentration measured by the concentration meter becomes less than the predetermined value. In carrying out these bubbling processes, the means for managing and controlling the gas bubbling may be provided with means for controlling the bubbling (for example, executing a step of increasing the amount of bubbling when the amount of gas injected or the pressure in the container of the mobile phase falls below a specified value) and / or means such as software for measuring and recording the amount of the injected inert gas, the pressure in the container for supplying the solvent used as the mobile phase, etc. Providing such means is preferable because record keeping is required as a means for ensuring the reliability of results obtained during, for example, pharmaceutical development, and such a requirement can be met.

[0016] The inert gas is not limited as long as it does not affect the analysis and can discharge dissolved oxygen, and examples of the inert gas that can be used include argon gas, helium gas, neon gas, krypton gas, xenon gas, nitrogen gas, etc. The inert gas may be one type or two or more types.

[0017] Another embodiment of the analytical method of the present invention includes using a mobile phase containing a basic ion pair reagent in a non-aqueous solvent as a step of preventing deterioration of the mobile phase. One non-limiting embodiment using a mobile phase containing a basic ion pair reagent in a non-aqueous solvent is described below. A mobile phase containing water and a mobile phase containing a basic ion pair reagent in a non-aqueous solvent are prepared separately in suitable containers. In addition to these, a further mobile phase may be used to form an appropriate mobile phase. The mobile phases are supplied from each container to a mixer using a pump having a function of delivering the liquid, and mixed.

[0018] The mixer is not particularly limited as long as it has the function of mixing two or more liquids uniformly at high speed, but examples of such mixers include mixers having at least one liquid distribution / mixing unit, and specifically, gradient mixers for liquid chromatography, etc.

[0019] The total flow rate when sending the liquids to the mixer is not particularly limited as long as it can contact and mix two or more liquids at high speed, and can be appropriately adjusted by a person skilled in the art depending on the type and internal volume of the mixer, the type of pump, etc. Specifically, the total flow rate of the liquids can be at least 0.25 times, 2.5 times, 25 times, 250 times, 2500 times, 25000 times, etc., per minute relative to the internal volume of the mixer.

[0020] The mixing ratio of the mobile phase containing water, the mobile phase containing a basic ion pair reagent in a non-aqueous solvent, and another mobile phase may be appropriately adjusted depending on the type of solvent, the concentration of the solution, the substances to be separated, the type of liquid chromatography column, etc. Mobile phase conditions in conventional liquid chromatography-mass spectrometry conditions using a basic ion pair reagent may also be referred to.

[0021] In this specification, the non-aqueous solvent includes not only a solvent that does not contain water at all, but also a solvent that excludes water as much as possible. For example, the organic solvent ratio can be 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, and particularly 40% or more is preferable, 60% or more is more preferable, and 80% or more is most preferable. The non-aqueous solvent is not particularly limited as long as it does not affect the analysis system and does not deteriorate the basic ion pair reagent, and examples thereof include alcohols such as methanol, ethanol, and propanol, and organic solvents such as acetonitrile. One or more types of non-aqueous solvents may be used. The mobile phase containing the basic ion pair reagent in the non-aqueous solvent may be subjected to bubbling of the mobile phase.

[0022] Examples of mobile phases include, but are not limited to, the following: Mobile phase A: water Mobile phase B: Methanol Mobile phase C: Methanol / hexafluoroisopropanol / triethylamine

[0023] The first embodiment, which prevents deterioration of the mobile phase due to bubbling using an inert gas, and the second embodiment, which prevents deterioration of the mobile phase using a non-aqueous solvent, may be implemented in combination, or the order in which the first embodiment and the second embodiment are implemented may be reversed.

[0024] <Sample> The sample to be used in the present invention is not particularly limited, and examples thereof include pharmaceutical samples, biological samples, food samples, etc. Pharmaceutical samples include, for example, pharmaceuticals, pharmaceutical raw materials, pharmaceutical additives, etc. The biological sample may be derived from any part of a living body, such as epithelium, epithelial gland, connective tissue, bone, blood, hematopoietic organ, muscle, nerve, visual organ, auditory organ, lymphatic system, integumentary system, cardiovascular system, respiratory system, urinary system, upper gastrointestinal tract, lower gastrointestinal tract, digestive gland, neuroendocrine system, endocrine system, reproductive system, sperm, or egg. Examples of the biological sample include whole blood, plasma, serum, breast milk, saliva, urine, stool, sputum, semen, or secretions, excretions or swabs of the vagina, nose, rectum, urethra, or pharynx, lacrimal duct secretions, biopsy tissue samples, brain-derived samples, liver-derived samples, kidney-derived samples, skin-derived samples, muscle-derived samples, heart-derived samples, esophagus-derived samples, stomach-derived samples, small intestine-derived samples (which may be derived from tissues spanning any one or more of the duodenum, jejunum, and ileum), appendix-derived samples, large intestine-derived samples (cecum, ascending intestine, Examples of tissue samples that may be used include, but are not limited to, a sample derived from the colon, transverse colon, descending colon, sigmoid colon, or rectum (or a sample derived from tissue spanning any one or more of the colon, transverse colon, descending colon, sigmoid colon, or rectum), anus, gallbladder, pancreas, ureter, spleen, bladder, adrenal gland, blood vessel, lymphatic vessel, lymph node, tongue, eyeball (vitreous body, ora serrata, ciliary muscle, zonula of Zinn, Schlemm's canal, pupil, anterior chamber, cornea, iris, lens cortex, lens nucleus, ciliary process, conjunctiva, inferior oblique muscle, inferior rectus muscle, medial rectus muscle, retinal artery and vein, optic nerve head (optic disc), or a sample derived from tissue spanning any one or more of the dura mater, central retinal artery, central retinal vein, optic nerve, vortex vein, Tenon's capsule, macula, fovea, sclera, choroid, superior rectus muscle, or retina). Examples of food-derived samples include foods, food ingredients, and food additives. The form of the sample is not particularly limited, and may be, for example, a liquid sample or a solid sample. In the case of a solid sample, a mixed liquid, an extract, a dissolution solution, or the like is prepared using a solvent or the like, and this can be used as the sample. The solvent is not particularly limited as long as it can dissolve the sample and does not affect the subsequent separation and detection, and examples of the solvent include water, physiological saline, and a buffer solution. The sample may be, for example, a sample containing an analyte, or a sample whose presence or absence of the analyte is unknown.The above sample may be subjected to appropriate pretreatment before analysis by the method of the present invention.

[0025] <Substances to be analyzed> The analyte is not particularly limited as long as it is an ionic substance, and includes various substances that are usually the subject of liquid chromatography-mass spectrometry. In the present invention, the ionic substance refers to a compound having an ionizable group, and may be a homopolymer of a monomer having an ionizable group, or a copolymer or condensation polymer with other monomers. The ion is not particularly limited as long as it is an anionic, and may be a compound having a group that can be anionized. It may also be an amphoteric substance that also has a group that can be cationized (hereinafter, it may be referred to as an anionic or amphoteric substance). In particular, the analysis method of the present invention can prevent deterioration of triethylamine and the like as a basic ion pair reagent, and can prevent deterioration of the mobile phase. Therefore, from the viewpoint of favorably exerting the effects of the analysis method of the present invention, an anionic or amphoteric analyte is preferably mentioned. Examples of such analytes include, but are not limited to, purine compounds, purine compound analogs, pyrimidine compounds, or nucleosides containing pyrimidine compound analogs, nucleotides, cyclic nucleotides, nucleotide diphosphates, and nucleotide triphosphates, nicotinamide adenine dinucleotide phosphate (NAD, NADPH), flavin adenine dinucleotide (FAD, FADH), coenzyme A (coenzyme A), tetrahydromethanopterin (H4MPT), S-adenosylmethionine (SAM), and coenzymes containing nucleosides such as 3'-phosphoadenosine-5'-phosphosulfate, metabolic intermediates thereof, and reduced hydrogen acceptors and modified products thereof, oligonucleotides, sugars, and sugar chains. The molecular weight of the analyte is not limited as long as it is possible to perform liquid chromatography-mass spectrometry. The analyte contained in the sample may be one or more types.

[0026] The oligonucleotide to be the analyte of the present invention is not particularly limited, and may be a nucleic acid such as DNA or RNA, or a modified nucleic acid. Preferred examples of oligonucleotides include nucleic acid drugs, such as antisense, decoy, siRNA, miRNA, ribozyme, CpG oligo and aptamer, and other oligonucleotides used in nucleic acid drugs. The modification of these nucleic acids is not particularly limited, and may be a modification of the 2' position of the sugar moiety (2'-F, 2'-O-Methyl (2'-OMe), 2'-O-Methoxyethyl (2'-MOE), etc.), a cross-linked modification (2',4'-BNA (2',4'-Bridged Nucleic Acid, also known as LNA (Locked Nucleic Acid)), etc.), phosphorothioation of the phosphate moiety (changing the oxygen atom double-bonded to phosphorus in the phosphate ester moiety to a sulfur atom), methylation of the nucleic acid moiety (5-methylcytosine (5-mC), etc.), etc., which are well known in the art. The oligonucleotide is not limited, but may be, for example, 10 to 100 bases, 10 to 80 bases, 10 to 50 bases, 10 to 50 bases, or 10 to 30 bases.

[0027] The sugars and sugar chains to be analyzed in the present invention are not particularly limited and may be monosaccharides, disaccharides, or oligosaccharides, and may be derived from simple carbohydrates consisting of sugars alone or complex carbohydrates containing other substances (including proteins, lipids, synthetic polymers, etc.), and may be natural or synthetic. The sugars and sugar chains in the present invention may be those to which sugar chains or complex carbohydrates such as glycoproteins, glycolipids, and proteoglycans are bound, but when analyzing trace amounts of sugar chains or complex carbohydrates derived from living organisms, the sugars and sugar chain portions may be isolated and collected and used as the analysis target. This pretreatment method can be appropriately selected by a person skilled in the art and used by setting the conditions according to the properties of the target substance to be analyzed. Known examples of such pretreatment methods include, but are not limited to, cleaving glycans with enzymes such as peptide N-glycosidase F (PNGaseF), chondroitinase, and heparinase, fragmenting the protein portion with proteases such as trypsin and actinase, chemically hydrolyzing hydrazinolysis, and reductive alkylation using urea and a surfactant such as sodium dodecyl sulfate (SDS). In addition, sugar chains and complex carbohydrates can be appropriately cleaved using an enzyme such as exoglycosidase depending on the purpose of measurement and then used for analysis. Preferred examples of sugars to be analyzed in the present invention include monosaccharides such as glucose, galactose, mannose, fucose, xylose, glucosamine, N-acetylglucosamine, galactosamine, and N-acetylgalactosamine, glucuronic acid, iduronic acid, and fructose, and disaccharides such as maltose, trehalose, sucrose, lactulose, isomaltose, lactose, lactosamine, N-acetyllactosamine, cellobiose, melibiose, and fragments of glycosaminoglycans (such as chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, heparan sulfate, and hyaluronic acid). Examples of oligosaccharides include maltooligosaccharides, isomaltooligosaccharides, lacto-oligosaccharides, lactosamine oligosaccharides, N-acetyllactosamine oligosaccharides, cello-oligosaccharides, melibio-oligosaccharides, and glycosaminoglycan fragments, and examples of monosaccharides include polyhydroxyaldehydes having approximately the same number of oxygen atoms as carbon atoms, polyhydroxyketones, and derivatives thereof (e.g., amino sugars having amino groups, carboxylic acids in which the aldehyde group or primary hydroxyl group is a carboxyl group, polyhydric alcohols in which the aldehyde group or ketone group is a hydroxyl group, etc.), and may refer to polymers thereof. In addition, the term "sialic acid" may refer to sialic acid that is present at the reducing end of a sugar chain or complex carbohydrate bound to a protein, lipid, etc., and that is present at the end of a sugar chain or oligosaccharide as a component of a sugar chain or complex carbohydrate. In this case, the term "sialic acid" may also include, for example, sialic acid derivatives in which the hydroxyl group has been modified by acetylation, and may be present even when it exists alone. The molecular weight of the sugar and sugar chain is not limited, but may be, for example, 100 to 5,000 Da, 300 to 3,000 Da, or 400 to 1,000 Da, as weight average molecular weight (Da) measured by the GPC-HPLC method.

[0028] Liquid chromatography / mass spectrometry The measurement of the sample in the analysis method of the present invention is carried out using liquid chromatography (LC) and a mass spectrometer (MS). Any device may be used as long as it uses a liquid chromatograph device and a mass spectrometer, and the respective devices may be connected in series with each other. As the device used in the method of the present invention, for example, an LC-MS system configured by connecting a liquid chromatograph device and a mass spectrometer in series can be preferably used. By using the LC-MS system, the components separated by liquid chromatography can be continuously subjected to mass analysis. As the LC-MS in which a mass spectrometer is connected to a liquid chromatograph, a tandem type LC-MS / MS, LC-MS / MS / MS, etc. can also be used.

[0029] [Liquid chromatography equipment] The liquid chromatography device is not particularly limited as long as it can separate the analyte contained in the sample by liquid chromatography, but is usually preferably an HPLC device. The HPLC device includes a separation column and a pump that sends the mobile phase to the separation column. The HPLC device may also include other elements such as a degasser, an autosampler, a heater, and a detector that detects the separated components. Examples of the detector include a UV detector and a fluorescence detector. For example, the detector can be connected between the column and the ion source (ionization section).

[0030] Liquid chromatography (LC) may be ultra-high performance liquid chromatography (hereinafter, sometimes referred to as UHPLC, UPLC, etc.), which allows for faster and more sensitive separation and analysis. UHPLC means liquid chromatography capable of high-pressure liquid delivery at about 100 MPa, and refers to an apparatus capable of analysis at higher speed and higher separation ability. In addition to the above-mentioned HPLC, the present invention also includes those called UHPLC, UPLC, etc. These apparatuses have in common that they are equipped with a pump that delivers the mobile phase to the separation column, and may be equipped with other elements such as a degasser, an autosampler, a heater, a detector, etc. Examples of detectors include a UV detector and a fluorescence detector.

[0031] UPLC uses columns packed with particles that can withstand high pressure, and can perform separation and analysis more quickly and with higher sensitivity than HPLC devices. Separation conditions using UPLC can be determined in the same manner as when setting HPLC conditions, and those skilled in the art can set the appropriate conditions. In addition, when applying conditions for a known HPLC analysis method to UPLC, conditions can also be determined using software such as ACQUITY UPLC Columns Calculator.

[0032] In the case of bubbling the mobile phase of liquid chromatography with an inert gas, the means for managing and controlling gas bubbling may be provided with a means for controlling bubbling and / or a means for measuring and recording the amount of inert gas blown in, the pressure in a container for supplying a solvent used as a mobile phase, etc., as a means for managing and controlling the gas bubbling. Providing such a means is preferable because, for example, record keeping is required as a means for ensuring the reliability of results obtained during drug development, and such a requirement can be met. Software may be used to manage such measurement records and set bubbling conditions. In such a case, the software for controlling the measurement conditions in a mass spectrometer, HPLC or UHPLC device may be capable of managing the measurement records and setting the bubbling conditions, or it may be used as separate independent software. For example, when using an LC-MS system configured by connecting a liquid chromatography device and a mass spectrometer in series, the HPLC or UHPLC conditions may be controlled on the mass spectrometer side, and in such a case, software for managing the measurement records and setting the bubbling conditions can be used in a computer connected to the mass spectrometer.

[0033] [Mobile phase] The conditions for the mobile phase (separation solution) used in high performance liquid chromatography are not particularly limited as long as it can separate the analyte and is a solvent applicable to a mass spectrometer. For example, water, methanol, ethanol, isopropanol, acetonitrile, etc. can be used. The solvent may be one type or two or more types. The mobile phase may contain other components as long as it can analyze the analyte.

[0034] For example, in the case of measuring ionic substances such as nucleic acid drugs having phosphate or thiophosphate groups, it is preferable to use acetylacetone and methanol as the mobile phase for the analysis. The use of acetylacetone is preferable because it improves the elution of poor peak shapes and carryover peaks caused by coordinate bonds between phosphate or thiophosphate groups of ionic substances and metal ions, and makes it possible to detect them. EDTA, which has the same effect as acetylacetone, may also be used. In addition, the use of methanol is preferable because it makes it possible to adjust the elution time of ionic substances such as oligonucleotides, sugars, and sugar chains.

[0035] In the analysis method of the present invention, the mobile phase of the liquid chromatography contains a basic ion pair reagent such as triethylamine (TEA) as an ion pair reagent in order to form an ion pair with an anionic or amphoteric sample and enable separation in a reversed phase column. The concentration of the basic ion pair reagent in the mobile phase can be appropriately set by a person skilled in the art depending on the analyte, and for example, when triethylamine is used, it can be appropriately selected depending on various conditions such as the type of analyte and the type of column, and may be, for example, 1 to 50 mM, or 1 to 20 mM, etc.

[0036] Furthermore, additives that do not affect the analysis can be added to the mobile phase for the purpose of facilitating separation or promoting the vaporization of basic ion pair reagents. Usable additives include acetic acid, ammonium hydroxide, ammonium formate (salt concentration = 100 mM or less), ammonium acetate (salt concentration = 100 mM or less), ammonium bicarbonate (salt concentration = 100 mM or less), trifluoroacetic acid (TFA), tetrahydrofuran (THF), hexafluoroisopropanol (HFIP), pentafluoropropanol (PFP), 1,1,1,3,3,3-hexafluoro-2-methyl-2-propanol (HFMIP), trifluoroethanol (TFE), or nonafluoro-tert-butyl alcohol (NFTB).

[0037] [Liquid chromatography conditions] The conditions of the analytical column used in liquid chromatography are not particularly limited and can be appropriately selected depending on various conditions such as the type of the substance to be analyzed and the type of sample. The separation column is not limited, but for example, a reversed-phase column can be used. Examples of reversed-phase columns include columns using ethylene-bridged hybrid (BEH) particles that are highly resistant to alkaline mobile phases, columns packed with octadecylsilylated silica gel packing material (ODS columns), C8 columns, C2 columns, and columns containing ion exchange resins. In particular, when performing analysis by HPLC, it is preferable to use a column packed with ethylene-bridged hybrid particles having a particle size of 5.0 μm or less (BEH column), and more preferably a BEH column having a particle size of 1.7 to 3.5 μm.

[0038] Other conditions used for liquid chromatography are not particularly limited and can be appropriately selected depending on conditions such as the type of analyte and the type of sample so that the analyte contained in the sample is separated from other components and eluted from the column. That is, in the separation step, the concentration of the mobile phase, such as methanol, in the mobile phase can be changed. Methanol may or may not be contained in the mobile phase throughout the entire separation step.

[0039] The elution method may be selected from isocratic elution and gradient elution methods as appropriate. It is of course necessary to sufficiently separate the object of measurement from impurities that can be seen on the chromatogram. It is also preferable to maintain a long retention time, since components derived from the matrix that cannot be seen on the chromatogram may adversely affect the ionization efficiency.

[0040] Specific gradient conditions include, for example, the conditions described in the Examples below. The gradient conditions are not particularly limited, and for example, ethanol, isopropanol, acetonitrile, etc. can be used instead of methanol.

[0041] Specifically, the separation step may include a step of increasing the methanol concentration in the mobile phase. That is, for example, a gradient may be applied to the methanol concentration so that the methanol concentration (v / v) in the mobile phase gradually increases from a first concentration (M1) to a second concentration (M2). M1 and M2 may be appropriately set according to various conditions such as the type of the substance to be analyzed and the type of impurities. The methanol concentration may be, for example, 0% or more, 1% or more, 3% or more, 5% or more, 10% or more, 20% or more, or 50% or more, and may be 100% or less, 99% or less, 75% or less, 50% or less, 25% or less, 20% or less, 15% or less, or 10% or less. The methanol concentration may be, for example, 10% to 90%. Specifically, for example, a gradient may be applied to the methanol concentration so that the methanol concentration (v / v) in the mobile phase gradually increases from 0% to 100%. The rate of change of the methanol concentration may be constant or may not be constant. The methanol concentration may repeatedly increase and decrease before changing from M1 to M2. The methanol concentration may further change after reaching M2. For example, the methanol concentration may further increase or decrease, or may repeatedly increase and decrease, after reaching M2. For example, the methanol concentration may repeatedly increase and decrease before changing again to M1 after reaching M2. For example, the methanol concentration may decrease to 0% after reaching M2.

[0042] A concentration gradient can be formed by mixing two or more solutions with different compositions while changing the mixing ratio. The combination of solutions can be appropriately selected so that the desired gradient is formed.

[0043] When preparing a mobile phase by mixing two or more solutions, the methanol concentration in the two or more solutions can be appropriately set according to the mixing ratio so that the methanol concentration in the mobile phase after mixing becomes the methanol concentration in the mobile phase exemplified above.

[0044] The pH of the mobile phase can be appropriately set according to various conditions such as the type of the analyte and the type of impurities. The composition and the preferred range of the pH of the mobile phase can be set so that the ionization efficiency of the analyte is high in mass spectrometry performed following liquid chromatography. That is, specifically, the composition and pH of the mobile phase at the time when the analyte is eluted from the column are preferably set so that the ionization efficiency of the analyte is high in mass spectrometry. The specific range is, for example, pH 1 to 14, preferably pH 4 to 12, and more preferably about pH 6 to 10.

[0045] The flow rate can be appropriately selected depending on various conditions such as the inner diameter of the separation column. The flow rate of the mobile phase may or may not be constant throughout the separation process. For example, it can be appropriately selected within the range of 0.001 to 2.0 mL / min according to the electrospray spectrometry (ESI). The flow rate of the mobile phase in liquid chromatography may be, for example, 0.05 to 1.0 mL / min. Furthermore, the column temperature in liquid chromatography can be appropriately selected by those skilled in the art according to the analysis target and the specifications of the analytical column to be used. For example, it may be 10 to 90°C, specifically, it may be about 30 to 80°C.

[0046] [Mass spectrometer] The mass spectrometer may be any known mass spectrometer, but one that can be connected in series to an LC device is particularly preferred because it can be used easily. One mass spectrometer, or two or more mass spectrometers may be used. Two or more mass spectrometers can be connected in parallel for use. The LC-MS system may be, for example, an LC-MS, LC-MS / MS or LC-MS nSpecifically, for example, Triple Quad (registered trademark) 5500, Triple Quad (registered trademark) 6500, Triple Quad (registered trademark) 6500+, QTRAP (registered trademark) 5500, QTRAP (registered trademark) 6500, QTRAP (registered trademark) 6500+, TripleTOF (registered trademark) 5600, TripleTOF (registered trademark) 5600+, TripleTOF (registered trademark) 6600, TripleTOF (registered trademark) 6600+, etc. manufactured by AB SCIEX, and Q Exactive (trademark) Focus, Q Exactive (trademark), Q Exactive (trademark) Plus, Q Exactive (trademark) HF, Q ​​Exactive (trademark) HF-X, Orbitrap ID-X Tribrid, Orbitrap Fusion (trademark) Tribrid (trademark), Orbitrap Fusion (trademark) Lumos (trademark) Tribrid manufactured by Thermo Fisher SCIENTIFIC. (trademark), Orbitrap Eclipse, etc.

[0047] Examples of detection methods in mass spectrometers include ion trap, quadrupole, quadrupole tandem, quadrupole ion trap hybrid, sector, time-of-flight, quadrupole time-of-flight hybrid, Fourier transform, and quadrupole Fourier transform hybrid. These can also be equipped with an ion mobility system. Examples of ionization methods in mass spectrometers include electrospray (ESI), atmospheric pressure chemical ionization (APCI), and photoionization (APPI). The detection method and ionization method can be appropriately selected depending on various conditions such as the type of the substance to be analyzed.

[0048] Since the spectrum and fragment ion spectrum (including accurate mass spectrum) obtained by mass spectrometry are values ​​specific to a substance, the ion ratio obtained by analysis of a standard and the spectrum and fragment ion spectrum (including accurate mass spectrum) obtained by analysis of a sample can be compared to identify the analyte contained in the sample. Specifically, the analyte contained in the sample can be identified by using a purified or synthesized analyte as the standard and comparing the spectrum (including accurate mass spectrum) obtained by analyzing the standard with the chromatogram obtained from the sample to be analyzed.

[0049] Furthermore, for an analyte for which no standard exists, if the analyte is unknown, it can be confirmed, for example, by structural estimation that a substance separated by liquid chromatography is the analyte, and then added to the analysis subject of the present invention. A person skilled in the art can appropriately select and carry out a method for confirming the unknown analyte, and for example, it can be confirmed that the analyte is the analyte by isolation and purification, etc.

[0050] Based on the results of mass spectrometry, the analyte can be quantified. The analyte can be quantified by a conventional method. Specifically, for example, the analyte can be quantified based on the peak area ratio (or peak height ratio) obtained by dividing the peak area value (or peak height value) of the detected analyte by the peak area value (or peak height value) of an internal standard substance with a known concentration.

[0051] The liquid chromatography device, mass spectrometer, and various elements included therein can be appropriately selected according to various conditions such as the type of substance to be analyzed and the type of impurities, with reference to the analytical conditions exemplified above.

[0052] <How to prevent deterioration of the mobile phase> A further aspect of the present invention relates to a method for preventing deterioration of a mobile phase, comprising bubbling a mobile phase of liquid chromatography containing a basic ion pair reagent (hereinafter, sometimes referred to as the "first method for preventing deterioration of a mobile phase of the present invention"). A further aspect of the present invention relates to a method for preventing deterioration of a mobile phase (hereinafter, sometimes referred to as the "second method for preventing deterioration of a mobile phase of the present invention"), comprising the steps of preparing a mobile phase in which a basic ion pair reagent is dissolved in a non-aqueous solvent, mixing the mobile phase with a mobile phase containing water, and using the mobile phase for liquid chromatography. The first method for preventing deterioration of a mobile phase of the present invention and the second method for preventing deterioration of a mobile phase of the present invention are capable of preventing deterioration of the mobile phase by preventing deterioration of a basic ion pair reagent in the mobile phase in liquid chromatography and liquid chromatography-mass spectrometry. The matters explained in the above analytical method of the present invention are all applicable to the explanation of the method of the present invention for preventing deterioration of a mobile phase.

[0053] <Analyzer> A further aspect of the present invention relates to an analytical apparatus (hereinafter, sometimes referred to as "the analytical apparatus of the present invention") comprising a liquid chromatography apparatus that separates a sample containing an ionic analyte and uses a mobile phase containing a basic ion pair reagent, a mass spectrometry apparatus that analyzes the analyte, and an apparatus for preventing deterioration of the mobile phase. The matters explained in the analytical method and the method for preventing deterioration of a mobile phase of the present invention are all applicable to the explanation of the analytical apparatus of the present invention.

[0054] One embodiment of the analysis device of the present invention will now be described, without being limited thereto. (1) a container for supplying a mobile phase containing a basic ion pair reagent; (2) a pump having a function of delivering the mobile phase; (3) A gas bubbling device for blowing an inert gas into the mobile phase to perform a bubbling process; (4) A liquid chromatography device for separating a sample containing an analyte; (5) A mass spectrometer that analyzes the target substance. Another embodiment of the analytical device of the present invention further includes a means and software for managing and controlling the bubbling of the mobile phase.

[0055] Another embodiment of the analysis device of the present invention will now be described. (1) a container for supplying a mobile phase containing water, and a container for supplying a mobile phase containing a basic ion pair reagent in a non-aqueous solvent; (2) a pump having a function of sending each of the above liquids to a mixing section; (3) A mixer capable of mixing two liquids uniformly and at high speed; (4) A liquid chromatography apparatus for separating a sample containing an analyte using the resulting mixture as a mobile phase; (5) A mass spectrometer that analyzes the target substance.

[0056] Yet another embodiment of the analysis device of the present invention will be described below. (1) a container for supplying a mobile phase containing water, a container for supplying a mobile phase containing an organic solvent, and a container for supplying a mobile phase containing a basic ion pair reagent in a non-aqueous solvent; (2) a pump having a function of sending each of the above liquids to a mixing section; (3) A mixer capable of mixing the three liquids uniformly and at high speed; (4) A liquid chromatography apparatus for separating a sample containing an analyte using the resulting mixture as a mobile phase; (5) A mass spectrometer that analyzes the target substance.

[0057] It should be noted that the above description is merely illustrative and does not indicate the application limits of the analysis device according to the present invention. In other words, the analysis device according to the present invention is not limited to the embodiments in this specification, and various modifications are possible without departing from the spirit of the present invention. EXAMPLES

[0058] The present invention will be described in detail below with reference to examples, but the scope of the present invention is not limited thereto.

[0059] Example 1: Preparation of standard solutions (1) Material The mipomersen (mipomersen-MOE) shown below and mipomersen prepared using other modified nucleic acids (mipomersen-LNA, mipomersen-OMe, mipomersen-S oligo) were purchased from Gene Design Co., Ltd. and used as standard substances. ·Mip-MOE G(m)^5(m)^5(m)^T(m)^5(m)^a^g^t^5(x)^t^g^5(x)^t^t^5(x)^G(m)^5(m)^A(m)^5(m)^5(m) ·Mipomersen-LNA (Mip-LNA) G(L)^5(L)^5(L)^T(L)^5(L)^a^g^t^5(x)^t^g^5(x)^t^t^5(x)^G(L)^5(L)^A(L)^5(L)^5(L) Mip-OMe G(M)^5(M)^C(M)^T(M)^C(M)^a^g^t^5(x)^t^g^5(x)^t^t^5(x)^G(M)^C(M)^A(M)^C(M)^C(M) Mipomersen-S-oligo (Mip-S-oligo) g^5(x)^5(x)^t^5(x)^a^g^t^5(x)^t^g^5(x)^t^t^5(x)^g^5(x)^a^5(x)^5(x)

[0060] [Table 1]

[0061] (2) Preparation of reagents The solvents used were methanol (Wako Pure Chemical Industries, Ltd., for LC / MS), 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) (Nacalai Tesque, for HPLC), triethylamine (TEA) (Thermo Scientific, sequencing grade), acetylacetone (Kanto Chemical, special grade), and Tris-EDTA buffer (TE) (Nippon Gene Co., Ltd.).

[0062] (i) Preparation of TE / methanol (7:3, v / v) Seven volumes of TE were mixed with three volumes of methanol.

[0063] (ii) Preparation of water / methanol / HFIP / TEA / acetylacetone (90:10:1:0.2:0.01, v / v / v / v / v) 90 volumes of water, 10 volumes of methanol, 1 volume of HFIP, 0.2 volumes of TEA, and 0.01 volumes of acetylacetone were mixed in. The container was covered with aluminum foil to keep it dark.

[0064] (iii) Preparation of water / methanol / HFIP / TEA (90:10:1:0.2, v / v / v / v) 90 volumes of water, 10 volumes of methanol, 1 volume of HFIP, and 0.2 volumes of TEA were mixed together. The container was covered with aluminum foil to keep it dark.

[0065] (iv) Preparation of methanol / water / HFIP / TEA / acetylacetone (90:10:1:0.2:0.01, v / v / v / v / v) Methanol (90 volumes), water (10 volumes), HFIP (1 volume), TEA (0.2 volumes), and acetylacetone (0.01 volumes) were mixed in. The container was covered with aluminum foil to keep it dark.

[0066] (v) Preparation of methanol / water / HFIP / TEA (90:10:1:0.2, v / v / v / v) 90 volumes of methanol, 10 volumes of water, 1 volume of HFIP, and 0.2 volumes of TEA were mixed together. The container was covered with aluminum foil to keep it dark.

[0067] (vi) Preparation of water / methanol / HFIP / TEA / acetylacetone (50:50:1:0.2:0.01, v / v / v / v / v) 50 volumes of water, 50 volumes of methanol, 1 volume of HFIP, 0.2 volumes of TEA, and 0.01 volumes of acetylacetone were mixed.

[0068] (3) Preparation of standard solutions Mipomersen-MOE, mipomersen-LNA, mipomersen-OMe, and mipomersen-S oligo were dissolved in DNase- and RNase-free purified water. 231.8 μg of mipomersen-MOE was added with 323 μL of purified water to completely dissolve, and the concentration was adjusted to 100 μmol / L, which was used as the mipomersen-MOE standard solution. 219.8 μg of mipomersen-LNA was added with 327 μL of purified water to completely dissolve, and the concentration was adjusted to 100 μmol / L, which was used as the mipomersen-LNA standard solution. 238.3 μg of mipomersen-OMe was added with 358 μL of purified water to completely dissolve, and the concentration was adjusted to 100 μmol / L, which was used as the mipomersen-OMe standard solution. 224.6 μg of mipomersen-S oligo was added with 349 μL of purified water to completely dissolve, and the concentration was adjusted to 100 μmol / L, which was used as the mipomersen-S oligo standard solution.

[0069] Mipomersen-MOE, mipomersen-LNA, mipomersen-OMe, and mipomersen-S oligo standard solutions were diluted 500-fold in water / methanol / HFIP / TEA / acetylacetone (50:50:1:0.2:0.01, v / v / v / v / v) to serve as mass spectrometer tuning solutions used to set optimal ionization conditions and select the ions to be measured.

[0070] The mipomersen-MOE, mipomersen-LNA, mipomersen-OMe, and mipomersen-S oligo standard solutions were diluted 2000-fold with TE / methanol (7:3, v / v) to prepare 50 nmol / L mixed solutions, which were used as standard solutions for monitoring spectral intensity.

[0071] Example 2: Determination of mass spectrometry conditions The mass spectrometer tuning solution was introduced into the ion source using a syringe pump, while the mixed mobile phase was introduced into the ion source together with the tuning solution using an HPLC pump (LC-20A, Shimadzu Corporation).

[0072] While checking the precursor ion (parent ion) to be used for quantification, the spray position of the ion source of the mass spectrometer (TripleTOF5600, AB SCIEX) was adjusted so that the intensity of this ion was maximized.

[0073] After completing the adjustment of the spray position, the declustering potential (orifice voltage; DP), the applied high voltage (ion spray voltage; IS), the gas pressures (GS1, GS2) and temperature (TEM) of GS1 and GS2 were adjusted.

[0074] Next, product ions (daughter ions) were searched from the precursor ions (parent ions), and the energy voltage (CE) involved in collision fragmentation was adjusted so that the ion intensity was maximized.

[0075] The mass spectrometry conditions determined by the above method are shown in Tables 2 and 3. The common ionization conditions are shown in Table 2. The mass spectrometry conditions (MS / MS conditions) for each component are shown in Table 3. Note that for mipomersen-MOE, mipomersen-LNA, and mipomersen-OMe, 9-valent ions and 10-valent ions were used as precursor ions, and for mipomersen-S oligo, 8-valent ions and 9-valent ions were used as precursor ions.

[0076] [Table 2]

[0077] [Table 3]

[0078] Example 3: Setting HPLC conditions Using the standard solution for spectral intensity monitoring prepared in Example 1, HPLC conditions for separating mipomersen-MOE, mipomersen-LNA, mipomersen-OMe, and mipomersen-S oligo were investigated.

[0079] As the HPLC apparatus, a Shimadzu LC-20A system (manufactured by Shimadzu Corporation) was used, and as the HPLC column, an ACQUITY UPLC Oligonucleotide BEH C18 Column (particle size 1.7 μm, inner diameter 2.1 mm × length 50 mm; manufactured by Waters) was used.

[0080] <HPLC Condition 1> In analyzing mipomersen-MOE and mipomersen-S oligo, a linear gradient condition was set using water / methanol / HFIP / TEA / acetylacetone (90:10:1:0.2:0.01, v / v / v / v / v) (mobile phase A) as the aqueous mobile phase and methanol / water / HFIP / TEA / acetylacetone (90:10:1:0.2:0.01, v / v / v / v / v) (mobile phase B) as the organic solvent-based mobile phase. The flow rate was 0.3 mL / min. An example of the gradient condition is shown in Table 4.

[0081] [Table 4]

[0082] <HPLC Condition 2> In analyzing mipomersen-MOE, mipomersen-LNA, and mipomersen-OMe, a linear gradient condition was set using water / methanol / HFIP / TEA (90:10:1:0.2:, v / v / v / v) (mobile phase A) as the aqueous mobile phase and methanol / water / HFIP / TEA (90:10:1:0.2, v / v / v / v) (mobile phase B) as the organic solvent-based mobile phase. The flow rate was 0.3 mL / min. An example of the gradient condition is shown in Table 5.

[0083] [Table 5]

[0084] Example 4: Confirmation of the Influence on the Measurement of Mipomersen-MOE and Mipomersen-S Oligo by the Presence or Absence of Nitrogen Bubbling in the Mobile Phase Using <HPLC condition 1>, the change in peak intensity in the continuous analysis of mipomersen-MOE and mipomersen-S oligo was confirmed under the conditions with and without nitrogen bubbling (2 mL / min) in the mobile phase (1 L). Also, the peak area ratio of mipomersen-MOE peak area value / mipomersen-S oligo peak area value was calculated, and the transition of the peak area ratio in the continuous analysis was also confirmed.

[0085] The transition of the peak area values of mipomersen-MOE and mipomersen-S oligo (160 consecutive analyses) without nitrogen bubbling is shown in Figure 1, the transition of the peak area ratio of mipomersen-MOE / mipomersen-S oligo (160 consecutive analyses) without nitrogen bubbling is shown in Figure 2, the transition of the peak area values of mipomersen-MOE and mipomersen-S oligo (160 consecutive analyses) with nitrogen bubbling is shown in Figure 3, and the transition of the peak area ratio of mipomersen-MOE / mipomersen-S oligo (160 consecutive analyses) with nitrogen bubbling is shown in Figure 4.

[0086] In the results of this study, since the absolute value of the slope of the approximate curve calculated from the transition of the peak area values shown in Figures 1 and 3 indicates the relationship of no nitrogen bubbling > with nitrogen bubbling in the mobile phase, it was revealed that the decrease in the peak areas of mipomersen-MOE and mipomersen-S oligo can be suppressed by applying nitrogen bubbling to the mobile phase. Also, assuming the internal standard method that is mainstream in quantitative analysis, when the peak area ratio of mipomersen-MOE and mipomersen-S oligo was obtained and an approximate curve was calculated, the absolute value of the slope similarly showed the relationship of no nitrogen bubbling > with nitrogen bubbling. This indicates that when nitrogen bubbling is applied to the mobile phase, the peak area ratio of the first measurement and the 160th measurement from the start of measurement is a similar value, meaning that the same sample is measured as the same quantitative value. Conversely, when nitrogen bubbling was not performed on the mobile phase, there was a deviation in the peak area ratio between the first measurement and the 160th measurement from the start of measurement, meaning that it was measured as a different quantitative value despite being the same sample, and the usefulness of applying nitrogen bubbling to the mobile phase became clear.

[0087] 《Example 5: Confirmation of the Influence of the Presence or Absence of Nitrogen Bubbling in the Mobile Phase on the Measurement of Mipomersen-MOE, Mipomersen-LNA, and Mipomersen-OMe》 For the purpose of confirming whether similar results can be obtained for compounds using modified nucleic acids other than those in Example 4, using <HPLC condition 2>, the change in peak intensity in the continuous analysis of mipomersen-MOE, mipomersen-LNA, and mipomersen-OMe was confirmed under the conditions of applying nitrogen bubbling to the mobile phase and not applying it.

[0088] The transition of the area values of mipomersen-MOE, mipomersen-LNA, and mipomersen-OMe (240 consecutive analyses) without nitrogen bubbling is shown in Figures 5 to 7, and the transition of the peak area values of mipomersen-MOE, mipomersen-LNA, and mipomersen-OMe (240 consecutive analyses) with nitrogen bubbling is shown in Figures 8 to 10.

[0089] From the results of this study, since the slope of the approximate curve calculated from the change in peak area values shows the relationship of without nitrogen bubbling > with nitrogen bubbling in the mobile phase, it was revealed that the decrease in the peak areas of mipomersen-MOE, mipomersen-LNA, and mipomersen-OMe can be suppressed by applying nitrogen bubbling to the mobile phase. Similar to Example 4, the usefulness of applying nitrogen bubbling to the mobile phase was revealed.

[0090] 《Example 6: Improvement Approach by Changing Mobile Phase Composition》 Using <HPLC condition 2>, the change in peak intensity in the continuous analysis of mipomersen-MOE was carried out under the condition of not performing nitrogen bubbling in the mobile phase. Subsequently, the peak intensity of mipomersen-MOE was confirmed when only the newly prepared organic solvent-based mobile phase was replaced and when only the newly prepared aqueous mobile phase was replaced. The results are shown in Figure 11.

[0091] From this study, it was suggested that the aqueous mobile phase deteriorates more easily than the organic solvent-based mobile phase. It became clear that the basic ion-pair reagent that causes deterioration can slow down the deterioration rate of the mobile phase by creating an environment where it exists only in a solution with a high organic solvent ratio. Therefore, it was suggested that improvement can be achieved by performing gradient analysis under the following mobile phase conditions. Mobile phase A: Water Mobile phase B: Methanol Mobile phase C: Methanol / HFIP / TEA (100:1:0.2, v / v / v) (It is still better to perform nitrogen bubbling on mobile phase C) A three-solvent gradient in which mobile phase C always flows at 10% and mobile phases A and B are gradiented

[0092] 《Example 7: Preparation of Standard Solution》 (1) Materials ΔUA-GalNAc, 4S (Chondroitin Sulfate A) shown below (C 14 H 19 NO 14SNa2, MW:503.34), ΔUA-GalNAc, 4S, 6S (Chondroitin Sulfate E)(C 14 H 18 NO 17 S2Na3, MW: 605.39) and ΔUA-2S GlcNCOEt-6S (internal standard) (C 15 H 20 NO 17 S2Na3 (MW: 619.42) was purchased from Iduron Ltd. and used as a standard substance.

[0093] (2) Preparation of reagents Solvents were prepared using acetonitrile (Wako Pure Chemical Industries, Ltd., for LC / MS), 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) (Nacalai Tesque, Inc., for HPLC), and n-Octylamine (OA) (Tokyo Chemical Industry Co., Ltd.).

[0094] (i) Preparation of water / HFIP / OA (100:1:0.124, v / v / v) 100 volumes of water, 1 volume of HFIP, and 0.124 volumes of OA were mixed together. The container was covered with aluminum foil to protect from light.

[0095] (ii) Preparation of acetonitrile / water / HFIP / OA (75:25:1:0.124, v / v / v / v) 75 volumes of acetonitrile, 25 volumes of water, 1 volume of HFIP, and 0.124 volumes of OA were mixed together. The container was covered with aluminum foil to protect from light.

[0096] (3) Preparation of standard solutions Chondroitin Sulfate A, Chondroitin Sulfate E and the internal standard were dissolved in Milli-Q (registered trademark) water to prepare the following concentrations. ·Chondroitin Sulfate A 5 mmol / L (CS-A) ·Chondroitin Sulfate E 2 mmol / L (CS-E) ·Internal standard substance 5 mmol / L (IS)

[0097] CS-A, CS-E, and IS were diluted 1000-fold with water / HFIP / OA (100:1:0.124, v / v / v) to prepare mass spectrometer tuning solutions used to set optimal ionization conditions and select ions to be measured.

[0098] CS-A, CS-E and IS were diluted 10,000-fold with water / HFIP / OA (100:1:0.124, v / v / v) to prepare mixed solutions, which were used as standard solutions to check changes in peak intensity during successive analyses.

[0099] Example 8: Determination of mass spectrometry conditions The mass spectrometer tuning solution was introduced into the ion source using a syringe pump, while the mixed mobile phase was introduced into the ion source together with the tuning solution using an HPLC pump (LC-20A, Shimadzu Corporation).

[0100] While checking the precursor ion (parent ion) to be used for quantification, the spray position of the ion source of the mass spectrometer (QTRAP5500, AB SCIEX) was adjusted so that the intensity of this ion was maximized.

[0101] After completing the adjustment of the spray position, the declustering potential (orifice voltage; DP), the applied high voltage (ion spray voltage; IS), the gas pressures (GS1, GS2) and temperature (TEM) of GS1 and GS2 were adjusted.

[0102] Next, product ions (daughter ions) were searched from the precursor ions (parent ions), and the energy voltage (CE) involved in collision fragmentation was adjusted so that the ion intensity was maximized.

[0103] The mass spectrometry conditions determined by the above method are shown in Tables 6 and 7. The common ionization conditions are shown in Table 6. The mass spectrometry conditions (MS / MS conditions) for each component are shown in Table 7.

[0104] [Table 6]

[0105]

Table 7

[0106] 《Example 9: Setting of HPLC Conditions》 Using the standard solution for confirming the change in peak intensity prepared in Example 1, HPLC conditions for separating Chondroitin Sulfate A, Chondroitin Sulfate E and the internal standard substance were investigated.

[0107] As the HPLC apparatus, a Shimadzu LC-20A system (manufactured by Shimadzu Corporation) was used, and as the HPLC column, an ACQUITY UPLC BEH C18 Column (particle size 1.7 μm, inner diameter 2.1 mm × length 100 mm; manufactured by Waters) was used.

[0108] <HPLC Conditions 3> In analyzing Chondroitin Sulfate A and E, linear gradient conditions were set using water / HFIP / OA (100:1:0.124, v / v / v) (mobile phase A) as the aqueous mobile phase and acetonitrile / water / HFIP / OA (75:25:1:0.124, v / v / v / v) (mobile phase B) as the organic solvent-based mobile phase. The flow rate was 0.2 mL / min. An example of the gradient conditions is shown in Table 8.

[0109]

Table 8

[0110] 《Example 10: Confirmation of the Influence of the Presence or Absence of Nitrogen Bubbling in the Mobile Phase on the Measurement of Chondroitin Sulfate A, Chondroitin Sulfate E and the Internal Standard Substance》 Using <HPLC condition 3>, the change in peak intensity in the continuous analysis of Chondroitin Sulfate A, Chondroitin Sulfate E, and the internal standard substance (ΔUA-2S GlcNCOEt-6S) was confirmed under the conditions with and without nitrogen bubbling (10 mL / min) in the mobile phase (1 L).

[0111] The change in the area value of Chondroitin Sulfate A (52 consecutive analyses) with and without nitrogen bubbling is shown in Fig. 12, the change in the area value of Chondroitin Sulfate E (52 consecutive analyses) with and without nitrogen bubbling is shown in Fig. 13, and the change in the peak area value of the internal standard substance (ΔUA-2S GlcNCOEt-6S) (52 consecutive analyses) with and without nitrogen bubbling is shown in Fig. 14.

[0112] In the results of this study, since the absolute value of the slope of the approximate curve calculated from the change in the peak area values shown in Figs. 12 to 14 shows the relationship of no nitrogen bubbling > with nitrogen bubbling, it was clarified that the decrease in the peak areas of Chondroitin Sulfate A, Chondroitin Sulfate E, and the internal standard substance (ΔUA-2S GlcNCOEt-6S) can be suppressed by subjecting the mobile phase to nitrogen bubbling.

Industrial Applicability

[0113] By using the method for preventing deterioration of the mobile phase of the present invention, in the measurement using a mass spectrometry system, it becomes possible to stably detect the peak height, peak area, peak height ratio, and peak area ratio of the compound to be measured and its internal standard substance over a long period of time. Therefore, many samples can be subjected to measurement in one measurement opportunity, and an accurate concentration measurement value can be obtained. Further, according to the present invention, there is no need for frequent replacement due to deterioration of the mobile phase. The reagents used for preparing the mobile phase are very expensive, and reduction of the cost burden and reduction of the labor time required for the preparer to prepare the reagents can also be expected.

Claims

1. 1. An analytical method comprising the steps of subjecting a sample containing an ionic analyte to liquid chromatography using a mobile phase containing a basic ion pair reagent, and then subjecting the sample to mass spectrometry, A method for analyzing a substance to be analyzed, comprising carrying out an operation for preventing deterioration of the basic ion pair reagent in the mobile phase.

2. The method according to claim 1, wherein the operation of preventing deterioration of the basic ion pair reagent in the mobile phase includes bubbling the mobile phase with an inert gas.

3. The method described in claim 2, wherein the operation of preventing deterioration of the basic ion pair reagent in the mobile phase further includes managing and controlling bubbling of the mobile phase with an inert gas.

4. A method according to any one of claims 1 to 3, wherein the operation of preventing deterioration of the basic ion pair reagent in the mobile phase includes using a mobile phase containing a basic ion pair reagent in a non-aqueous solvent.

5. The method according to claim 1, wherein the basic ion pair reagent is an amine compound.

6. The basic ion pair reagent is tetraethylammonium hydroxide (TEA-OH), tetrabutylammonium hydroxide (TBAOH), N,N-dimethylbutylamine (DMBA), octylamine, OA, tripropylamine (TPA), N,N-dimethylhexylamine (DMHA), diisopropylamine (DIA), Propylamine (DIPA), N-methyldibutylamine (MDBA), Propylamine (PA), Triethylamine (TEA), hexylamine (HA), tributylamine (TBA), N,N-dimethylcyclohexylamine (DMCHA), N,N-diisopropylethylamine (DIEA), tetraethylamine (TEA), trimethylethylenediamine (TMEDA), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), dipropylammonium acetate (DPAA), dibutylammonium acetate (DBAA), diamylammonium acetate (DAAA), and dihexylammonium acetate The method according to any one of claims 1 to 5, wherein the disaccharide is at least one selected from the group consisting of DHAA.

7. The method according to claim 1, wherein the ionic analyte is at least one selected from the group consisting of a purine compound, a purine compound analog, a pyrimidine compound, or a nucleoside containing a pyrimidine compound analog; a nucleotide, a cyclic nucleotide, a nucleotide diphosphate, and a nucleotide triphosphate; a coenzyme containing a nucleoside selected from nicotinamide adenine dinucleotide phosphate (NAD, NADPH), flavin adenine dinucleotide (FAD, FADH), coenzyme A, tetrahydromethanopterin (H4MPT), S-adenosylmethionine (SAM), and 3'-phosphoadenosine-5'-phosphosulfate; metabolic intermediates thereof, and reduced hydrogen acceptors and modified forms thereof; and an oligonucleotide, a sugar, and a sugar chain.

8. The oligonucleotide is an antisense, decoy, siRNA, miRNA, ribozyme, CpG The method according to claim 7, wherein the nucleic acid pharmaceutical is at least one type selected from oligos and aptamers.

9. The method according to claim 7, wherein the sugar and sugar chain are at least one type selected from monosaccharides, disaccharides, and oligosaccharides.

10. The method according to claim 2, wherein the inert gas is at least one selected from the group consisting of nitrogen gas, argon gas, neon gas, krypton gas, xenon gas and helium gas.

11. The method includes a step of bubbling a mobile phase of liquid chromatography containing a basic ion pair reagent; A method for preventing deterioration of a basic ion pair reagent in the mobile phase.

12. The method includes a step of preparing a mobile phase in which a basic ion pair reagent is dissolved in a non-aqueous solvent, mixing the mobile phase with a mobile phase containing water, and using the mobile phase in liquid chromatography. A method for preventing deterioration of a basic ion pair reagent in the mobile phase.

13. A liquid chromatography apparatus for separating a sample containing an ionic analyte using a mobile phase containing a basic ion pair reagent; A mass spectrometer for analyzing the target substance; and A device for preventing deterioration of the basic ion pair reagent in the mobile phase; An analysis device comprising:

14. The analytical apparatus of claim 13, wherein the deterioration prevention device for the basic ion pair reagent in the mobile phase is a gas bubbling device for the mobile phase.

15. The analytical apparatus described in claim 14, wherein the device for preventing deterioration of the basic ion pair reagent in the mobile phase further includes means and software for managing and controlling bubbling of the mobile phase.

16. The analytical apparatus of claim 13, wherein the device for preventing deterioration of the basic ion pair reagent in the mobile phase is a device that mixes a mobile phase containing a basic ion pair reagent in a non-aqueous solvent with a mobile phase containing water.

Citation Information

Patent Citations

  • Functional assay of high-density lipoproteins

    JP2003529775A

  • Methods for analyzing oligonucleotides

    JP2012500394A